Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Dec 31, 2026 to Oct 15, 2021
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description revised
  2. 6 versions Re-verified since Nov 1, 2025, no change to tracked fieldsv9-v14
  3. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2026v8
  4. 2 versions Re-verified since May 3, 2025, no change to tracked fieldsv6-v7
  5. Interventions: Biopsy (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Echocardiography (Procedure), Magnetic Resonance… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Echocardiography Test (Procedure)…v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary and study completion dates: Mar 24, 2025 to Dec 31, 2025v4
  2. 2 versions Re-verified since May 7, 2024, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II MATCH treatment trial tests how well BVD-523FB (ulixertinib) works in treating patients with cancer that has certain genetic changes. BVD-523FB (ulixertinib) is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of proteins that signal cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Trial Details
NCT Number NCT06400225
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Related terms Lymphoma, Multiple Myeloma
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov